Cited by 402Advanced Breast Cancer TherapiesCancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 285 of the 292 references it cites were found in a registry or an index.

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Open access

Whittaker, Steven R., Mallinger, Aurélie, Workman, Paul, Clarke, Paul A.·2017·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2017.02.008PMC PMC6141011

Open this paper in CoChat — free account

Abstract

Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer. CDKs have now been shown to regulate other processes, particularly various aspects of transcription. The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers. The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors. However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest. Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER+/HER2- advanced breast cancer. Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compounds that have allowed exploration of individual CDKs as cancer targets and the determination of their potential therapeutic windows. Biomarkers that allow the selection of patients likely to respond are now being discovered. Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors. This suggests that the selective inhibitors may be best used combined with standard of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2017.02.008

Cites

285 of 285 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 5,008
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“In any case, RB remains phosphorylated throughout the S, G2 and M phases, and at the end of mitosis it is dephosphorylated by protein phosphatase 1 (Malumbres & Barbacid, 2009).”
The Role of Chromatin during Transcription
Li, B., Carey, M., & Workman, J. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.015 · Cited by 3,503
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Cyclin-dependent kinases
Malumbres, M. (2014) · Genome biology · doi:10.1186/gb4184 · Cited by 1,730
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
Jeffrey, P. D., Russo, A. A., Polyák, K., Gibbs, E., Hurwitz, J., Massagué, J., & Pavletich, N. P. (1995) · Nature · doi:10.1038/376313a0 · Cited by 1,455
Cyclin A is required at two points in the human cell cycle.
Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. J., & Draetta, G. F. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05135.x · Cited by 1,403
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“However, notably in mice bearing human breast and colorectal xenografts oral treatment with palbociclib induced tumor regressions, with confirmed inhibition of RB phosphorylation in tumor lysates (Fry et al., 2004).”
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L’Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,210
Cdk1 is sufficient to drive the mammalian cell cycle
Santamarı́a, D., Barrière, C., Cerqueira, A., Hunt, S. L., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P. R., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,096
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
The Mediator complex: a central integrator of transcription
Allen, B. L., & Taatjes, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3951 · Cited by 922
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N. P., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B. M., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 865
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Priéto, I., Odajima, J., Martín, A. L., Dubus, P. R., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 798
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
In vitro disassembly of the nuclear lamina and M phase-specific phosphorylation of lamins by cdc2 kinase
Peter, M., Nakagawa, J., Dorée, M., Labbé, J., & Nigg, E. A. (1990) · Cell · doi:10.1016/0092-8674(90)90471-p · Cited by 782
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
Herrera-Abreu, M. T., Palafox, M., Asghar, U. S., Rivas, M. A., Cutts, R. J., García-Murillas, I., Pearson, A., Guzmán, M., Rodríguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 781
mTORC1 controls the adaptive transition of quiescent stem cells from G0 to GAlert
Rodgers, J. T., King, K. Y., Brett, J. O., Cromie, M. J., Charville, G. W., Maguire, K. K., Brunson, C., Mastey, N., Liu, L., Tsai, C.-R., et al. (2014) · Nature · doi:10.1038/nature13255 · Cited by 776
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700 · cited 6×
“However, cells from other tissues in these embryos proliferate normally, indicating that Cdk4/6 are primarily required for haematopoesis in early development.”
Influential
Myt1: A Membrane-Associated Inhibitory Kinase That Phosphorylates Cdc2 on Both Threonine-14 and Tyrosine-15
Mueller, P. R., Coleman, T. R., Kumagai, A., & Dunphy, W. G. (1995) · Science · doi:10.1126/science.270.5233.86 · Cited by 698
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 692
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
A Long Twentieth Century of the Cell Cycle and Beyond
Nurse, P. (2000) · Cell · doi:10.1016/s0092-8674(00)81684-0 · Cited by 631
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Chipumuro, E., Marco, E., Christensen, C. L., Kwiatkowski, N. P., Zhang, T., Hatheway, C. M., Abraham, B. J., Sharma, B., Yeung, C. M., Altabef, A. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.024 · Cited by 631
Mastermind Recruits CycC:CDK8 to Phosphorylate the Notch ICD and Coordinate Activation with Turnover
Fryer, C. J., White, B., & Jones, K. A. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.014 · Cited by 627
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10875-10894.2005 · Cited by 627
Structural basis of cyclin-dependent kinase activation by phosphorylation
Russo, A. A., Jeffrey, P. D., & Pavletich, N. P. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-696 · Cited by 599
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
Parry, D., Guzi, T. J., Shanahan, F., Davis, N. M., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M. P., Doll, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0324 · Cited by 562
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 530
The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522
The RNA Polymerase II Carboxy-Terminal Domain (CTD) Code
Eick, D., & Geyer, M. (2013) · Chemical Reviews · doi:10.1021/cr400071f · Cited by 500
Cyclin-dependent kinases: a family portrait
Malumbres, M., Harlow, E. E., Hunt, T., Hunter, T. R., Lahti, J. M., Manning, G., Morgan, D. O., Tsai, L., & Wolgemuth, D. J. (2009) · Nature Cell Biology · doi:10.1038/ncb1109-1275 · Cited by 499
Cyclin D activates the Rb tumor suppressor by mono-phosphorylation
Narasimha, A. M., Kaulich, M., Shapiro, G. S., Choi, Y. J., Siciński, P., & Dowdy, S. F. (2014) · eLife · doi:10.7554/elife.02872 · Cited by 496
Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases
Zarkowska, T., & Mittnacht, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12738 · Cited by 494
Regulation of cell proliferation by the E2F transcription factors
Helin, K. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80058-0 · Cited by 491
Proliferation of cancer cells despite CDK2 inhibition
Tetsu, O., & McCormick, F. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00053-9 · Cited by 472
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Wang, Y., Zhang, T., Kwiatkowski, N. P., Abraham, B. J., Lee, T. I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.063 · Cited by 464
Uniform transitions of the general RNA polymerase II transcription complex
Mayer, A., Lidschreiber, M., Siebert, M., Leike, K., Söding, J., & Cramer, P. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1903 · Cited by 446
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Christensen, C. L., Kwiatkowski, N. P., Abraham, B. J., Carretero, J., Al‐Shahrour, F., Zhang, T., Chipumuro, E., Herter-Sprie, G. S., Akbay, E. A., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.019 · Cited by 446
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Ras Links Growth Factor Signaling to the Cell Cycle Machinery via Regulation of Cyclin D1 and the Cdk Inhibitor p27KIP1
Aktaş, H., Cai, H., & Cooper, G. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3850 · Cited by 410
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Pelish, H. E., Liau, B. B., Nitulescu, I. I., Tangpeerachaikul, A., Poss, Z. C., Silva, D. H. D., Caruso, B., Arefolov, A., Fadeyi, O., Christie, A. L., et al. (2015) · Nature · doi:10.1038/nature14904 · Cited by 406
CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1Preprint
Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010) · Genes & Development · doi:10.1101/gad.1968210 · Cited by 404
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Dickson, M. A., Tap, W. D., Keohan, M. L., D'Angelo, S. P., Gounder, M. M., Antonescu, C. R., Landa, J., Qin, L.-X., Rathbone, D. D., Condy, M. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5476 · Cited by 399
Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II
Larochelle, S., Amat, R., Glover-Cutter, K. M., Sansó, M., Zhang, C., Allen, J. J., Shokat, K. M., Bentley, D. L., & Fisher, R. P. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2399 · Cited by 398
Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27 Kip1 Activity
Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7011 · Cited by 395
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A., & Knudsen, E. S. (2010) · Oncogene · doi:10.1038/onc.2010.154 · Cited by 393
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M. E., Blum, K. A., Rovin, B. H., Brooker-McEldowney, M., et al. (2006) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 393
Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma
Huang, J., Deng, Q., Wang, Q., Li, K. Y., Dai, J.-H., Li, N., Zhu, Z. D., Zhou, B., Liu, X. Y., Liu, R.-F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2391 · Cited by 391
HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia
Galbraith, M. D., Allen, M. A., Bensard, C., Wang, X., Schwinn, M. K., Qin, B., Long, H. W., Daniels, D. L., Hahn, W. C., Dowell, R. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.048 · Cited by 379
MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research
Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R., & Johnson, M. D. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9392-8 · Cited by 374
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol
Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L., Zhao, H. G., Davis, R. E., Sathyamoorthy, M., et al. (2001) · Genome biology · doi:10.1186/gb-2001-2-10-research0041 · Cited by 371
Human Mediator Subunit MED26 Functions as a Docking Site for Transcription Elongation Factors
Takahashi, H., Parmely, T. J., Sato, S., Tomomori‐Sato, C., Banks, C. A. S., Kong, S. E., Szutorisz, H., Swanson, S. K., Martin‐Brown, S., Washburn, M. P., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.005 · Cited by 369
CDK8 is a positive regulator of transcriptional elongation within the serum response network
Donner, A. J., Ebmeier, C. C., Taatjes, D. J., & Espinosa, J. M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1752 · Cited by 368
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0509 · Cited by 366
The Mediator complex and transcription regulation
Poss, Z. C., Ebmeier, C. C., & Taatjes, D. J. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.840259 · Cited by 364
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressorPreprint
Kalinichenko, V. V., Major, M. L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H. M., Dennewitz, M. B., Shin, B., Datta, A., Raychaudhuri, P., et al. (2004) · Genes & Development · doi:10.1101/gad.1200704 · Cited by 358
Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein
Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J. B., Bernards, R., DeCaprio, J. A., & Ewen, M. E. (1997) · Nature · doi:10.1038/386177a0 · Cited by 356
Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design
Wyatt, P. G., Woodhead, A., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Davis, D., Devine, L. A., Early, T. R., Feltell, R. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800382h · Cited by 346
Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase
Peter, M., Nakagawa, J., Dorée, M., Labbé, J., & Nigg, E. A. (1990) · Cell · doi:10.1016/0092-8674(90)90093-t · Cited by 345
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients
Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337
STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells
Khodarev, N. N., Beckett, M., Labay, E., Darga, T. E., Roizman, B., & Weichselbaum, R. R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308102100 · Cited by 328
The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expressionPreprint
Sadasivam, S., Duan, S., & DeCaprio, J. A. (2012) · Genes & Development · doi:10.1101/gad.181933.111 · Cited by 323
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Infante, J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R. K., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1248 · Cited by 318
FoxM1B Is Overexpressed in Human Glioblastomas and Critically Regulates the Tumorigenicity of Glioma Cells
Liu, M., Dai, B., Kang, S.-H., Ban, K., Huang, F.-J., Lang, F. F., Aldape, K., Xie, T., Pelloski, C. E., Xie, K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2912 · Cited by 314
E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8
Morris, E. J., Ji, J., Yang, F., Stefano, L. D., Herr, A., Moon, N. S., Kwon, E. J., Haigis, K. M., Näär, A. M., & Dyson, N. J. (2008) · Nature · doi:10.1038/nature07310 · Cited by 306
Mediator Is a Transducer of Wnt/β-Catenin Signaling
Kim, S., Xu, X., Hecht, A., & Boyer, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602696200 · Cited by 298
CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response
Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dölken, L., Strobl, B., Müller, M., Taatjes, D. J., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.017 · Cited by 297
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 293
Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero
Brandeis, M., Rosewell, I. R., Carrington, M., Crompton, T., Jacobs, M. A., Kirk, J. A., Gannon, J., & Hunt, T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4344 · Cited by 290
Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1
MacCallum, D. E., Melville, J., Frame, S., Watt, K. J. C., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0233 · Cited by 289
Cell Cycle Control of Wnt Receptor Activation
Davidson, G. R., Shen, J., Huang, Y., Su, Y., Karaulanov, E., Bartscherer, K., Hassler, C., Stannek, P., Boutros, M., & Niehrs, C. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.11.006 · Cited by 284
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene
Murphy, M., Stinnakre, M., Sénamaud‐Beaufort, C., Winston, N. J., Sweeney, C., Kubelka, M., Carrington, M., Bréchot, C., & Sobczak‐Thépot, J. (1997) · Nature Genetics · doi:10.1038/ng0197-83 · Cited by 279
Structure, Function, and Activator-Induced Conformations of the CRSP Coactivator
Taatjes, D. J., Näär, A. M., Andel, F., Nogales, E., & Tjian, R. (2002) · Science · doi:10.1126/science.1065249 · Cited by 277
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potentialPreprint
Wong, P., 岩崎, 正., Somervaille, T. C. P., So, C. W. E., & Cleary, M. L. (2007) · Genes & Development · doi:10.1101/gad.1602107 · Cited by 274
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
Benson, C., White, J., Bono, J. S. D., O’Donnell, A. E., Raynaud, F. I., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S. B., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Self-citation
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
Kumar, S. K., LaPlant, B. R., Chng, W. J., Zonder, J. A., Callander, N. S., Fonseca, R., Fruth, B. F., Roy, V., Erlichman, C., & Stewart, A. K. (2014) · Blood · doi:10.1182/blood-2014-05-573741 · Cited by 256
Yeast Nuclear Extract Contains Two Major Forms of RNA Polymerase II Mediator Complexes
Liu, Y., Ranish, J. A., Aebersold, R. H., & Hahn, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009586200 · Cited by 255
Human Cyclin a Is Required for Mitosis until Mid Prophase
Furuno, N., den Elzen, N. R., & Pines, J. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.2.295 · Cited by 254
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M. A., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 254
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Sánchez-Martínez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.100 · Cited by 240
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
Wang, S., & Fischer, P. M. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.003 · Cited by 236
The Mediator complex: a master coordinator of transcription and cell lineage development
Yin, J., & Wang, G. (2014) · Development · doi:10.1242/dev.098392 · Cited by 236
The Human CDK8 Subcomplex Is a Histone Kinase That Requires Med12 for Activity and Can Function Independently of Mediator
Knuesel, M. T., Meyer, K. D., Donner, A. J., Espinosa, J. M., & Taatjes, D. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00993-08 · Cited by 234
Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
Iorns, E. J., Turner, N. C., Elliott, R. J. R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N. J., Crook, T., Lord, C. J., & Ashworth, A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.001 · Cited by 230
Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells
Balmanno, K., & Cook, S. J. (1999) · Oncogene · doi:10.1038/sj.onc.1202647 · Cited by 227
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
A Universal RNA Polymerase II CTD Cycle Is Orchestrated by Complex Interplays between Kinase, Phosphatase, and Isomerase Enzymes along Genes
Bataille, A. R., Jerónimo, C., Jacques, P., Laramée, L., Fortin, M.-È., Forest, A., Bergeron, M., Hanes, S. D., & Robert, F. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.11.024 · Cited by 220
Regulation of lipogenesis by cyclin-dependent kinase 8–mediated control of SREBP-1
Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X.-J., Zhou, J., Sun, Y., Yang, E. S. T., Liu, L., Vaitheesvaran, B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61462 · Cited by 219
A conserved Mediator–CDK8 kinase module association regulates Mediator–RNA polymerase II interaction
Tsai, K.-L., Sato, S., Tomomori-Sato, C., Conaway, R. C., Conaway, J. W., & Asturias, F. J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2549 · Cited by 219
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Tong, W.-G., Chen, R., Plunkett, W. K., Siegel, D. S. D., Sinha, R., Harvey, R. D., Badros, A. Z., Popplewell, L. L., Coutre, S. E., Fox, J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1347 · Cited by 217
New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Kauraniemi, P., Barlund, M. T., Monni, O. M., & Kallioniemi, A. H. (2001) · PubMed · Cited by 214
Molecular Pathways: Interferon/Stat1 Pathway: Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth
Khodarev, N. N., Roizman, B., & Weichselbaum, R. R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3225 · Cited by 206
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaPreprint
Huang, C., Lujambio, A., Zuber, J. A., Tschaharganeh, D. F., Doran, M. G., Evans, M. J., Kitzing, T. M., Zhu, N., de Stanchina, E., Sawyers, C. L., et al. (2014) · Genes & Development · doi:10.1101/gad.244368.114 · Cited by 204
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 201
Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma
Schwartz, G. K., Ilson, D. H., Saltz, L. B., O'Reilly, E. M., Tong, W. P., Maslak, P. G., Werner, J., Perkins, P., Stoltz, M., & Kelsen, D. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.1985 · Cited by 197
The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
Whittaker, S. R., Walton, M. I., Garrett, M. D., & Workman, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0110 · Cited by 196
Self-citation
Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing
Liang, K., Gao, X., Gilmore, J. M., Florens, L. A., Washburn, M. P., Smith, E. R., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 194
RNA Polymerase II C-Terminal Domain: Tethering Transcription to Transcript and Template
Corden, J. L. (2013) · Chemical Reviews · doi:10.1021/cr400158h · Cited by 192
The structure and substrate specificity of human Cdk12/Cyclin K
Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M. (2014) · Nature Communications · doi:10.1038/ncomms4505 · Cited by 191
3′ end formation of pre-mRNA and phosphorylation of Ser2 on the RNA polymerase II CTD are reciprocally coupled in human cellsPreprint
Davidson, L., Muniz, L., & West, S. (2014) · Genes & Development · doi:10.1101/gad.231274.113 · Cited by 183
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
Harbeck, N., Iyer, S. S., Turner, N. C., Cristofanilli, M., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Bhattacharyya, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw139 · Cited by 180
Ins and Outs of Kinase DFG Motifs
Treiber, D. K., & Shah, N. P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.001 · Cited by 177
Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities
Porter, D. C., Farmaki, E., Altilia, S., Schools, G. P., West, D. K., Chen, M., Chang, B.-D., Puzyrev, A. T., Lim, C., Rokow-Kittell, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206906109 · Cited by 177
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 172
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing
Nilson, K. A., Guo, J., Turek, M. E., Brogie, J. E., Delaney, E., Luse, D. S., & Price, D. H. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.032 · Cited by 170
Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling
Rocha, P. P., Scholze‐Wittler, M., Bleiß, W., & Schrewe, H. (2010) · Development · doi:10.1242/dev.053660 · Cited by 170
Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1
Polier, G., Ding, J., Konkimalla, V. B., Eick, D., Ribeiro, N., Köhler, R., Giaisi, M., Efferth, T., Désaubry, L., Krammer, P. H., et al. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.66 · Cited by 167
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Tourneau, C. L., Faivre, S. J., Laurence, V., Delbaldo, C., Vera, K., Girre, V., Chiao, J. H., Armour, S., Frame, S., Green, S. R., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.08.001 · Cited by 166
CDK11 Complexes Promote Pre-mRNA Splicing
Hu, D., Mayeda, A., Trembley, J. H., Lahti, J. M., & Kidd, V. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210057200 · Cited by 166
Activation of FoxM1 during G2 Requires Cyclin A/Cdk-Dependent Relief of Autorepression by the FoxM1 N-Terminal Domain
Laoukili, J., Álvarez‐Fernández, M., Meijer, L. A. T., Stahl, M., Mohammed, S., Kleij, L., Heck, A. J. R., & Medema, R. H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01710-07 · Cited by 164
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
Sonawane, Y. A., Taylor, M., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00150 · Cited by 164
How do small GTPase signal transduction pathways regulate cell cycle entry?
Marshall, C. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00044-7 · Cited by 161
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Siemeister, G., Lücking, U., Wengner, A. M., Lienau, P., Steinke, W., Schatz, C. A., Mumberg, D., & Ziegelbauer, K. B. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0286 · Cited by 161
Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
Mita, M. M., Joy, A. A., Mita, A. C., Sankhala, K. K., Jou, Y., Zhang, D., Statkevich, P., Zhu, Y., Yao, S., Small, K. A., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.016 · Cited by 155
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
Bose, P., Simmons, G. L., & Grant, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.789859 · Cited by 154
Mitosis-specific phosphorylation of nucleolin by p34cdc2 protein kinase.
Belenguer, P., Caizergues‐Ferrer, M., Labbé, J., Dorée, M., & Amalric, F. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.7.3607 · Cited by 150
The Role of Cdk5 in Neuroendocrine Thyroid Cancer
Pozo, K., Castro‐Rivera, E., Tan, C., Plattner, F., Schwach, G., Siegl, V., Meyer, D. A., Guo, A., Gundara, J. S., Mettlach, G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.027 · Cited by 150
Distinct sub‐populations of the retinoblastoma protein show a distinct pattern of phosphorylation.
Mittnacht, S., Lees, J. A., Desai, D. M., Harlow, E., Morgan, D. O., & Weinberg, R. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06241.x · Cited by 150
E2F-associated chromatin modifiers and cell cycle control
Blais, A., & Dynlacht, B. D. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.10.003 · Cited by 146
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
Dale, T. C., Clarke, P. A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M.-J., Mallinger, A., Samant, R. S., Czodrowski, P., Müsil, D., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1952 · Cited by 146
Self-citation
Cleavage of PITSLRE Kinases by ICE/CASP-1 and CPP32/CASP-3 during Apoptosis Induced by Tumor Necrosis Factor
Beyaert, R., Kidd, V. J., Cornelis, S., de Craen, M. V., Denecker, G., Lahti, J. M., Gururajan, R., Vandenabeele, P., & Fiers, W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11694 · Cited by 144
Identification and Characterization of the CDK12/Cyclin L1 Complex Involved in Alternative Splicing Regulation
Chen, H.-H., Wang, Y.-C., & Fann, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2736-2745.2006 · Cited by 144
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity
Marzec, M., Kasprzycka, M., Lai, R. L., Gladden, A. B., Wlodarski, P. K., Tomczak, E. Z., Nowell̀, P. C., DePrimo, S. E., Sadis, S., Eck, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016634 · Cited by 143
Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
Johnson, N., Cai, D. D., Kennedy, R. D., Pathania, S., Arora, M., Li, Y.-C., D’Andrea, A. D., Parvin, J. D., & Shapiro, G. I. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.036 · Cited by 141
Cdk8 Is Essential for Preimplantation Mouse Development
Westerling, T., Kuuluvainen, E., & Mäkelä, T. P. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01302-06 · Cited by 141
The Structure of CDK8/CycC Implicates Specificity in the CDK/Cyclin Family and Reveals Interaction with a Deep Pocket Binder
Schneider, E. V., Böttcher, J., Blaesse, M., Neumann, L., Huber, R., & Maskos, K. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.07.020 · Cited by 140
Pygopus activates Wingless target gene transcription through the mediator complex subunits Med12 and Med13
Carrera, I., Janody, F., Leeds, N. B., Duveau, F., & Treisman, J. E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709749105 · Cited by 138
FoxM1 Regulates Transcription of JNK1 to Promote the G1/S Transition and Tumor Cell Invasiveness
Wang, I., Chen, Y., Hughes, D. E., Ackerson, T. J., Major, M. L., Kalinichenko, V. V., Costa, R. H., Raychaudhuri, P., Tyner, A. L., & Lau, L. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709892200 · Cited by 137
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
Goh, K. C., Novotny-Diermayr, V, Hart, S., Ong, L. C., Loh, Y. K., Cheong, A., Tan, Y. C., Hu, C., Jayaraman, R., William, A. D., et al. (2012) · Leukemia · doi:10.1038/leu.2011.218 · Cited by 135
Identification of Molecular Vulnerabilities in Human Multiple Myeloma Cells by RNA Interference Lethality Screening of the Druggable Genome
Tiedemann, R. E., Zhu, Y. X., Schmidt, J. E., Chang, S., Sereduk, C., Yin, H. H., Mousses, S., & Stewart, A. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2781 · Cited by 135
The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain
Jerónimo, C., Collin, P., & Robert, F. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.006 · Cited by 135
The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation
Petretti, C., Savoian, M. S., Montembault, É., Glover, D. M., Prigent, C., & Giet, R. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400639 · Cited by 134
Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors
Loyer, P., Trembley, J. H., Grenet, J. A., Busson, A., Corlu, A., Zhao, W., Koçak, M., Kidd, V. J., & Lahti, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708188200 · Cited by 133
Expression Signature of IFN/STAT1 Signaling Genes Predicts Poor Survival Outcome in Glioblastoma Multiforme in a Subtype-Specific Manner
Duarte, C. W., Willey, C. D., Zhi, D., Cui, X., Harris, J. J., Vaughan, L. K., Mehta, T. S., McCubrey, R. O., Khodarev, N. N., Weichselbaum, R. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029653 · Cited by 133
CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
Putz, E. M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.012 · Cited by 132
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
CrkRS
Ko, T. K., Kelly, E., & Pines, J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.14.2591 · Cited by 132
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
Nemunaitis, J. J., Small, K. A., Kirschmeier, P. T., Zhang, D., Zhu, Y., Jou, Y., Statkevich, P., Yao, S., & Bannerji, R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-259 · Cited by 131
Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion
Ganuza, M., Sáiz-Ladera, C., Cañamero, M., Goméz-López, G., Schneider, R. P., Blasco, M. A., Pisano, D. G., Paramio, J. M., Santamarı́a, D., & Barbacid, M. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.94 · Cited by 131
Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities
Shao, H., Shi, S., Huang, S., Hole, A. J., Abbas, A. Y., Baumli, S., Liu, X., Lam, F., Foley, D., Fischer, P. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301475f · Cited by 130
Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Brasca, M. G., Amboldi, N., Ballinari, D., Cameron, A. D., Casale, E., Cervi, G., Colombo, M., Colotta, F., Croci, V., D’Alessio, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9006559 · Cited by 130
In vitro and In vivo Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202
Raynaud, F. I., Whittaker, S. R., Fischer, P. M., McClue, S. J., Walton, M. I., Barrie, S. E., Garrett, M. D., Rogers, P., Clarke, S. J., Kèlland, L. R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2264 · Cited by 130
Self-citation
Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
Finn, R., Crown, J. P., Láng, I., Boér, K., Bondarenko, I., Kulyk, S. V., Ettl, J., Patel, R., Pintér, T., Schmidt, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s1-6 · Cited by 128
Mice thrive without Cdk4 and Cdk2
Barrière, C., Santamarı́a, D., Cerqueira, A., Galán, J., Martín, A. L., Ortega, S., Malumbres, M., Dubus, P. R., & Barbacid, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.03.001 · Cited by 125
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Byth, K. F., Thomas, A. P., Hughes, G. D., Forder, C. L., McGregor, A., Geh, C., Oakes, S. E., Green, C., Walker, M., Newcombe, N. J., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0836 · Cited by 124
Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805
Byrd, J. C., Peterson, B. L., Gabrilove, J. L., Odenike, O. M., Grever, M. R., Rai, K., Larson, R. A., & the Cancer and Leukemia Group B (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2276 · Cited by 123
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
Flynn, J. M., Jones, J. A., Johnson, A. J., Andritsos, L. A., Maddocks, K. J., Jaglowski, S. M., Hessler, J. D., Grever, M. R., Im, E., Zhou, H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.31 · Cited by 123
Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.
Gopinathan, L., Tan, S. L. W., Padmakumar, V. C., Coppola, V., Tessarollo, L., & Kaldis, P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3440 · Cited by 123
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening
Czodrowski, P., Mallinger, A., Wienke, D., Esdar, C., Pöschke, O., Busch, M., Rohdich, F., Eccles, S. A., Ortiz-Ruiz, M.-J., Schneider, R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00597 · Cited by 123
Self-citation
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Joshi, K., Rathos, M. J., Joshi, R., Sivakumar, M., Mascarenhas, M., Kamble, S., Lal, B., & Sharma, S. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0613 · Cited by 121
TFIIH and P-TEFb Coordinate Transcription with Capping Enzyme Recruitment at Specific Genes in Fission Yeast
Viladevall, L., Amour, C. V. S., Rosebrock, A. P., Schneider, S., Zhang, C., Allen, J. J., Shokat, K. M., Schwer, B., Leatherwood, J., & Fisher, R. P. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.01.029 · Cited by 120
The Writers, Readers, and Functions of the RNA Polymerase II C-Terminal Domain Code
Jerónimo, C., Bataille, A. R., & Robert, F. (2013) · Chemical Reviews · doi:10.1021/cr4001397 · Cited by 120
The CDK Network: Linking Cycles of Cell Division and Gene Expression
Fisher, R. P. (2012) · Genes & Cancer · doi:10.1177/1947601912473308 · Cited by 118
Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitor
Albert, T., Rigault, C., Eickhoff, J., Baumgart, K., Antrecht, C., Klebl, B., Mittler, G., & Meisterernst, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12408 · Cited by 117
Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity
Kasten, M. M., & Giordano, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204295 · Cited by 117
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
Mallinger, A., Schiemann, K., Rink, C., Stieber, F., Calderini, M., Crumpler, S., Stubbs, M., Adeniji-Popoola, O., Poeschke, O., Busch, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01685 · Cited by 117
Self-citation
CDK8 Maintains Tumor Dedifferentiation and Embryonic Stem Cell Pluripotency
Adler, A. S., McCleland, M. L., Truong, T., Lau, S., Modrusan, Z. D., Soukup, T. M., Roose‐Girma, M., Blackwood, E. M., & Firestein, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3886 · Cited by 116
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
Heath, E. I., Bible, K. C., Martell, R. E., Adelman, D. C., & LoRusso, P. M. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9090-3 · Cited by 114
Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer
Brägelmann, J., Klümper, N., Offermann, A., von Mäßenhausen, A., Böhm, D., Deng, M. C.-H. K., Queisser, A., Sanders, C., Syring, I., Merseburger, A. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0094 · Cited by 112
Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
William, A. D., Lee, A. C.-H., Goh, K. C., Blanchard, S., Poulsen, A., Teo, E. L., Nagaraj, H., Lee, C. P., Wang, H., Williams, M. R. V., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201112g · Cited by 109
Cooperative activity of cdk8 and GCN5L within Mediator directs tandem phosphoacetylation of histone H3
Meyer, K. D., Donner, A. J., Knuesel, M. T., York, A. G., Espinosa, J. M., & Taatjes, D. J. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.78 · Cited by 109
CDK8 expression in 470 colorectal cancers in relation to β‐catenin activation, other molecular alterations and patient survival
Firestein, R., Shima, K., Nosho, K., Irahara, N., Baba, Y., Bojarski, E. F., Giovannucci, E. L., Hahn, W. C., Fuchs, C. S., & Ogino, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24908 · Cited by 109
PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).
Finn, R. S., Martín, M., Rugo, H. S., Jones, S. E., Im, S., Gelmon, K. A., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.507 · Cited by 109
Targeting Cdk11 in osteosarcoma cells using the CRISPR‐cas9 system
Feng, Y., Sassi, S. O., Shen, J. K., Yang, X., Gao, Y., Osaka, E., Zhang, J., Yang, S., Cao, Y., Mankin, H. J., et al. (2014) · Journal of Orthopaedic Research® · doi:10.1002/jor.22745 · Cited by 108
Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents
Wang, S., Griffiths, G., Midgley, C., Barnett, A. L., Cooper, M. R., Grabarek, J., Ingram, L., Jackson, W., Kontopidis, G. A., McClue, S. J., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.07.016 · Cited by 107
Rb-mediated chromatin structure regulation and transcriptional repression
Zhang, H. S., & Dean, D. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204338 · Cited by 107
Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6
Tiedemann, R. E., Zhu, Y. X., Schmidt, J. E., Yin, H. H., Shi, C.-X., Que, Q. Q., Basu, G. D., Azorsa, D. O., Perkins, L. M., Braggio, E., et al. (2009) · Blood · doi:10.1182/blood-2009-09-243980 · Cited by 106
A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene
Ye, X., Zhu, C., & Harper, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1682 · Cited by 105
Cortistatin A is a High‐Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11
Cee, V. J., Chen, D. Y. ‐., Lee, M. R., & Nicolaou, K. C. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200904778 · Cited by 105
Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts.
Strelkov, I. S., & Davie, J. (2002) · PubMed · Cited by 104
Phase II study of flavopiridol in patients with advanced colorectal cancer
Aklilu, M., Kindler, H. L., Donehower, R. C., Mani, S., & Vokes, E. E. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg343 · Cited by 102

Sorted by citations

Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Cell cycle control in cancer
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. W. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 807
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Lin, A., Giuliano, C. J., Palladino, A. C., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 769
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Ding, L., Cao, J., Lin, W.-S., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 655

See all 402

Authors: Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A.
Affiliations: Institute of Cancer Research (GB)
Corresponding author: Clarke, Paul A.
ORCID: Whittaker, Steven R.
Workman, Paul
Clarke, Paul A.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2017-05
Volume: 173
Pages: 83-105
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2017.02.008
PMC: PMC6141011
OpenAlex: W2583136106
Cited by: 384
References: 292
Citations by year: 2026: 25 · 2025: 38 · 2024: 37 · 2023: 47 · 2022: 38 · 2021: 53 · 2020: 55 · 2019: 51 · 2018: 25 · 2017: 15
FWCI: 7.38
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Cancer Research UK (C309/A11566, C368/A6743, A368/A7990)
Topics: Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: cyclin-dependent kinases, cyclin-dependent kinase inhibitors, isoform-selective inhibitors, CDK4/6 inhibitors, palbociclib, breast cancer, cell cycle regulation, tumor cell proliferation, biomarkers, drug resistance, combination therapy, protein kinase inhibitors
MeSH terms: Animals, Antineoplastic Agents, Cell Cycle, Humans, Neoplasms, Drug Design, Cyclin-Dependent Kinases, Protein Kinase Inhibitors, Cell Proliferation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks